1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional) is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), NIH. This program supports translational activities and clinical feasibility studies to advance the development of therapeutic and diagnostic devices for disorders affecting the nervous or neuromuscular systems.
It aims to develop treatments such as closed-loop systems for brain disorders including Parkinson's disease and major depressive disorder. Individuals, institutions, or businesses developing their own devices or with established collaborations with device manufacturers are encouraged to apply.
Get alerted about grants like this
Save a search for “National Institute of Neurological Disorders and Stroke (NINDS), NIH” or related topics and get emailed when new opportunities appear.
Search similar grants →Based on current listing details, eligibility includes: Individuals, institutions, or businesses developing their own devices or with established collaborations with device manufacturers. For more information see BP MedTech website. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Not specified Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is January 29, 2028. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Federal grant success rates typically range from 10-30%, varying by agency and program. Build a strong proposal with clear objectives, measurable outcomes, and a well-justified budget to improve your chances.
Requirements vary by sponsor, but typically include a project narrative, budget justification, organizational capability statement, and key personnel CVs. Check the official notice for the complete list of required attachments.
Yes — AI tools like Granted can help research funders, draft proposal sections, and check compliance. However, always review and customize AI-generated content to reflect your organization's unique strengths and the specific requirements of the solicitation.
Review timelines vary by funder. Federal agencies typically take 3-6 months from submission to award notification. Foundation grants may be faster, often 1-3 months. Check the program's timeline in the official solicitation for specific dates.
Many federal programs offer multi-year funding or allow competitive renewals. Check the official solicitation for continuation and renewal policies. Non-competing continuation applications are common for multi-year awards.
Past winners and funding trends for this program
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) is a National Institutes of Health funding opportunity inviting Research Project Grant applications proposing to study the ethical, legal, and social implications of human genetic and genomic research. Applications may use single or mixed methods including empirical qualitative and quantitative approaches, conceptual analyses, legal analyses, and normative analyses. Applied research addressing ELSI issues in genetics and genomics is also considered. Multiple NIH institutes participate, including NHGRI, NIMH, NCI, and others. Direct community engagement is encouraged but not required.
Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Not Allowed) is a funding opportunity from the National Institutes of Health supporting exploratory and innovative neuroscience research within the shared missions of NINDS and NIMH. Awards support early-stage conceptual projects that assess the feasibility of novel research directions, including the development of new techniques, agents, methodologies, or models of high value to the neuroscience community. Clinical trials are not accepted under this program. Applications follow NIH standard due dates with multiple submission cycles per year. Eligible applicants include academic institutions, nonprofits, and other organizations meeting NIH requirements.
Pain Therapeutics Development Program (PTDP) (UG3/UH3 Clinical Trial Optional) is sponsored by National Institute of Neurological Disorders and Stroke (NINDS), NIH HEAL Initiative. This program supports preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. It is a milestone-driven phased cooperative agreement focusing on facilitating drug discovery and development in academic and small business settings.